Long-term Outcomes of Patients with Rheumatoid Arthritis in Remission

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDiakonhjemmet Hospital

About this trial

The goal of this multi-center prospective observational study is to develop knowledge on how to best personalize treatment and follow-up strategies for patients with RA in remission, with the intention to prevent relapse of disease activity and progression of joint damage and at the same time avoid the use of unnecessary treatment and health resources.

The investigators will perform an extensive evaluation of all patients who participated in the ARCTIC REWIND study 10 and 15 years after they achieved sustained remission and received different treatment strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Participation in the ARCTIC REWIND trial

Patients able and willing to give written informed consent and comply with the requirements of the study protocol

Disqualifiers

Psychiatric or mental disorders, alcohol abuse, other substance abuse, other factors making adherence to the study protocol impossible.

Trial population

The study population consists of men and women with established rheumatoid arthritis who have experienced sustained remission and participated in the ARCTIC REWIND trial. All the 259 patients that entered the ARCTIC REWIND trial are eligible to participate in the extension study.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Disease activity remission status

Remission status will be assessed according to e.g the disease activity score DAS, the Simplified Disease Activity Index (SDAI) and ACR/EULAR Boolean 2.0 remission. DAS includes the ritchie articular index, the swollen joint count (based on 44 joints), the ESR and the Patient's Global Assessment of disease activity on a VAS 0-100 mm (PGA). The following cut-points are used: High disease activity: DAS \> 3.7; Moderate disease activity: 3.7 ≥ DAS\>2.4; Low disease activity: 2.4 ≥ DAS ≥ 1.6; In remission: DAS \< 1.6 The SDAI includes tender and swollen joints (of 28), PGA, PhGA and CRP. According to SDAI, the following cut-points are used: High disease activity: SDAI\> 26.0; Moderate disease activity: 26.0 ≥ SDAI\>11.0; Low disease activity: 11.0 ≥ SDAI \> 3.3; In remission: SDAI ≤ 3.3 ACR/EULAR 2.0 remission is defined as the combination of tender joints ≤ 1, swollen joints ≤ 1, CRP ≤ 1 and patient global assessment ≤ 2 (on a scale 0-10).

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial
2

Disease Modifying Anti-Rheumatic Drug (DMARD)-free remission

The prevalence of DMARD-free remission

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial
3

Radiographic score (van der Heijde modified Sharp score (vdHSS)

Radiographs of hands and feet. The van der Heijde-modified Sharp scoring method will be used, which assesses erosions in 16 joints of each hand (range, 0-5 for each joint) and in 6 joints of each foot (range, 0-10 per joint) and joint space narrowing in 15 joints for each hand and in 6 joints for each foot (range, 0-4 per joint).This gives scores for erosions on a scale from 0 to 280 and joint space narrowing on a scale from 0 to168, thus the total van der Heijde-modified Sharp score ranges from 0 to 448, with higher scores indicating greater joint damage.

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial
4

Radiographic joint damage progression

Radiographs of hands and feet. The van der Heijde-modified Sharp scoring method will be used, which assesses erosions in 16 joints of each hand (range, 0-5 for each joint) and in 6 joints of each foot (range, 0-10 per joint) and joint space narrowing in 15 joints for each hand and in 6 joints for each foot (range, 0-4 per joint).This gives scores for erosions on a scale from 0 to 280 and joint space narrowing on a scale from 0 to168, thus the total van der Heijde-modified Sharp score ranges from 0 to 448, with higher scores indicating greater joint damage. The images will be compared to the last corresponding images undertaken in the ARCTIC REWIND trial. Progression will be calculated as e.g. annual increase in van der Heijde modified Sharp score ≥ 1 unit.

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial

Secondary outcomes

1

Health-related quality of life

EuroQol-5 Dimensions three-level (EQ-5D-3L) is a utility instrument for measurement of health-related quality of life. It comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems (labelled 1-3). They have no arithmetic properties and should not be used to derive a summary score. To derive the summary index score an appropriate value set is required, which provides values (weights) for each health state description according to the preferences of the general population of a country/region

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial
2

Patient global assessment of disease activity

0-100 visual analogue scale (VAS), with higher scores Indicating more disease activity

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial
3

Physician global assessment of disease activity

0-100 visual analogue scale (VAS), with higher scores Indicating more disease activity

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial
4

Ultrasound inflammation

Ultrasound joint inflammation will be assessed by use of a validated 0-3 semi-quantitative scoring system for power Doppler and grey scale with an ultrasound atlas as reference. In the total ultrasound score 32 joints will be included: Bilateral metacarpophalangeal (MCP) joint I-V, radiocarpal joint, distal radioulnar joint, intercarpal joint, elbow, knee, talocrural joint and metatarsophalangeal (MTP) joint I-V, yielding a maximum total score of 96. In addition to the 32 joints the following will be scored: Bilateral proximal Interphalangeal (PIP) 2 and 3 joints, extensor carpi ulnaris tendon and tibialis posterior tendon.

Time frame
Assessed at the visit 10- and 15-year after the initial inclusion into the ARCTIC REWIND trial

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Diakonhjemmet Hospital

Lead sponsor

South-Eastern Norway Regional Health Authority

Collaborator

The Research Council of Norway

Collaborator

Olav Thon Foundation

Collaborator

This trial is not recruiting at the moment. You can still explore other options: